Search

Rationale: The onset of cytokine release syndrome (CRS) and in vivo persistence of anti-CD19 chimeric antigen receptor T (CAR-T) cells after infusion correlate with clinical responsiveness. However, there are no known baseline biomarkers that can predict the prognosis of patients with B-lineage non-Hodgkin lymphoma (B-NHL). The aim of this study was to identify blood cell populations associated with beneficial outcomes in B-NHL patients administered CAR-T cell immunotherapies. Methods: We enumerated peripheral blood and CAR-T cells by retrospectively analyzing three CAR-T cell trials involving 65 B-NHL patients. We used a preclinical model to elucidate the eosinophil mechanism in CAR-T cell therapy. Results: During an observation period up to 30 mo, B-NHL patients with higher baseline eosinophil counts had higher objective response rates than those with low eosinophil counts. Higher baseline eosinophil counts were also significantly associated with durable progression-free survival (PFS). The predictive significance of baseline eosinophil counts was validated in two independent cohorts. A preclinical model showed that eosinophil depletion impairs the intratumoral infiltration of transferred CAR-T cells and reduces CAR-T cell antitumor efficacy. Conclusion: The results of this study suggest that peripheral eosinophils could serve as stratification biomarkers and a recruitment machinery to facilitate anti-CD19 CAR-T cell therapy in B-NHL patients.

Automated building fault detection and diagnostics (AFDD) has become a valuable tool to maintain the efficiency of high-performance buildings. Still, when faults are detected or diagnosed, they are often presented to the building operators as-is with little explanation of their potential impacts. This could lead to higher workload and knowledge requirement for the operators to assess the situation and schedule maintenance tasks. One approach to aid the building operators' decision-making process is to provide quantitative impact metrics for faults. Metrics such as energy, thermal comfort, and cost can be simulated using building performance simulation (BPS) software or data-driven models. While BPS has been used in fault detection research as well as advanced control algorithms, little work has done to introduce BPS to fault evaluation and fault management applications. This paper proposes a standardized procedure to use BPS to evaluate diagnosed faults in building systems by quantifying symptoms caused by faults, and then translate these symptoms to BPS inputs. This research tries to tackle the challenges of uncertainties caused by parameter estimation and providing strategies to symptoms that cannot be directly translated to a BPS input. The proposed method can be generalized to be integrated with existing FDD tools or future FDD research., eSim 2018, May 9-10, 2018, Montreal, QC, Canada

3045Background: Cellular immunotherapy based on chimeric antigen receptor (CAR)-engineered T (CAR-T) cells has shown to be one of the most promising immunotherapeutic strategies for cancer treatmen...

8020Background: Encouraging results are seen from several early phase clinical trials on the cellular immunotherapy based on chimeric antigen receptor (CAR)-engineered T (CAR-T) targeting B cell ma...